Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-1.15% $5.17
America/New_York / 25 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 308.87 mill |
EPS: | -1.260 |
P/E: | -4.10 |
Earnings Date: | May 10, 2024 |
SharesOutstanding: | 59.74 mill |
Avg Daily Volume: | 0.346 mill |
RATING 2024-04-25 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.10 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.70x |
Company: PE -4.10 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-1.538 (-129.76%) $-6.71 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 4.71 - 5.63 ( +/- 8.88%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Waksal Harlan | Buy | 275 000 | Common Stock |
2024-03-18 | Palasis Maria | Buy | 500 000 | Stock Option |
2024-01-30 | Bishop John E | Buy | 200 000 | Stock Options |
2024-01-30 | Nieman Richard | Buy | 200 000 | Stock Options |
2024-01-30 | Cavalier Jason | Buy | 200 000 | Stock Options |
INSIDER POWER |
---|
100.00 |
Last 92 transactions |
Buy: 35 062 945 | Sell: 0 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $5.17 (-1.15% ) |
Volume | 0.105 mill |
Avg. Vol. | 0.346 mill |
% of Avg. Vol | 30.45 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:31 | sell | $4.83 | N/A | Active |
---|
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.